Form 4: Xeris Biopharma CEO Reports Equity Grants & Tax Withholdings

Xeris Biopharma Holdings CEO John Patrick Shannon Jr. reported the acquisition of restricted stock units and stock options, alongside tax-related share disposals.

Summary

• John Patrick Shannon Jr., CEO and Director of Xeris Biopharma Holdings, Inc. (XERS), reported changes in his beneficial ownership.
• On January 30, 2026, Mr. Shannon acquired 478,436 shares of Common Stock through a restricted stock unit (RSU) grant under the Company's 2018 Stock Option and Incentive Plan.
• These RSUs represent a contingent right to receive one share of common stock and will vest in equal annual installments over three years, subject to continued employment.
• Also on January 30, 2026, Mr. Shannon acquired 639,639 stock options with an exercise price of $7.36 per share, granted under the same plan.
• These stock options will also vest in equal annual installments over three years, subject to continued service, and expire on January 30, 2036.
• On January 31, 2026, Mr. Shannon disposed of a total of 340,505 shares of Common Stock (118,134, 111,621, and 110,750 shares) at a price of $7.36 per share.
• These disposals represent shares withheld by the Issuer to satisfy income tax and withholding obligations related to the net settlement of restricted stock units that vested as of January 31, 2026.
• Following these transactions, Mr. Shannon beneficially owns 2,935,578 shares of Common Stock and 639,639 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting standard executive compensation practices that align management incentives with long-term company performance, despite the routine tax-related share disposals.

Positives

• The grant of 478,436 restricted stock units and 639,639 stock options aligns management's interests with long-term shareholder value, as vesting is contingent on continued employment/service over three years.
• Equity compensation is a standard practice to incentivize executive performance and retention.

Negatives

• The disposal of 340,505 shares, while for tax purposes, reduces the direct shareholding of the CEO, though this is a common practice for RSU vesting.

Future Outlook

The restricted stock units and stock options granted to the CEO are structured to vest in equal annual installments over three years, indicating a forward-looking incentive for continued leadership and performance through at least January 2029.

Industry Context

StockSavvy.ai notes that the use of restricted stock units and stock options as a significant component of executive compensation is a prevalent practice across the biopharmaceutical industry. This structure aims to align executive incentives with long-term company performance and shareholder interests, a common strategy for talent retention and motivation in a competitive sector like biopharma.

Comparison to Industry Standards

• The equity compensation structure, involving both restricted stock units and stock options with multi-year vesting, is consistent with typical executive compensation packages observed in the U.S. biopharmaceutical industry.
• The tax withholding of shares upon RSU vesting is a standard mechanism to cover statutory tax obligations, mirroring practices at comparable companies such as BioNTech SE or Moderna, Inc. for their executive equity awards.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial interests with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: The compensation structure may serve as a benchmark or signal for broader employee incentive programs, fostering a performance-oriented culture.

Next Steps

• The restricted stock units and stock options will vest in equal annual installments over the next three years, subject to continued employment/service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the grant of equity awards and subsequent tax-related share disposals upon vesting. Such transactions are standard and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation. A 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, CEO, Beneficial Ownership